TY  - GEN

T1  - 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

PY  - 2023/01/25

AU  - Weidinger S

AU  - Cork M

AU  - Reich A

AU  - Bieber T

AU  - Gilbert S

AU  - Brennan N

AU  - Wilson R

AU  - Lucchesi D

AU  - Rynkiewicz N

AU  - Stebegg M

AU  - Porter-Brown B

ED  - 

Y2  - 2024/12/22

ER  -